INTRODUCTION
Leishmaniasis remains a major public health problem throughout the tropics. The current outbreak of kala-azar or visceral leishmaniasis caused by Leishmania donovani sensu strictu in eastern and southern Sudan has taken its toll on an impoverished, war-stricken population, killing tens of thousands and depopulating vast areas of southern Sudan. The calamity brought kala-azar to the forefront as one of the greatest epidemics of the 20th century (Perea et al. 1989; De Beer et al. 1990 ). Post kala-azar dermal leishmaniasis following drug treatment causes additional problems, as do the dramatic and debilitating cutaneous forms of disease that occur throughout tropical regions of both the Old and New Worlds. Even in sub-tropical regions where disease has not traditionally caused a major problem in humans, sub-clinical status is elevated to clinical disease in association with HIV infection (Rosenthal et al. 2000) . There are no vaccines in routine use, and chemotherapy still relies principally on antimonial-based drugs first used in the early 20th century.
The 35 Mb genome of Leishmania should be sequenced by late 2002. It contains approximately 8500 genes that it is assumed will translate into more than 10 000 proteins. The question is: how rapidly can we harness the power of the genome-proteome to learn more about the biology of the host-parasite interaction and to develop new drugs and new vaccines? In our laboratory we have focussed on DNA-vaccine technology to develop higher throughput screens for potential new vaccine candidates. Initially the following two questions were considered.
(i) Could we narrow down the number of genes to be tested as vaccines by prescreening for genes expressed in forms of the parasite that invade and survive in the vertebrate host? (ii) Could we test DNA vaccines in pools? 3 5 7 10 LA day 3 5 7 10 LA day 3 5 7 10 LA day 3 5 7 10 LA day 3 5 7 10 LA day 3 5 7 10 LA day 3 5 7 10 LA day 3 5 7 10 LA day 3 5 7 10 LA day 3.00 4.00 3 5 7 10 LA day 3 5 7 10 LA day 3 5 7 10 LA day Figure 1 . Results of partition-based clustering of expression profiles for one experiment in which RNAs from different points in the development cycle (days 3, 5, 7, 10 for promastigotes grown in Schneider's insect medium) for L. major LV39. See § 2 for further description of the analysis.
EXPRESSION PROFILING USING cDNA MICROARRAYS
The analysis of gene expression at the RNA level using microarray techniques can provide a global genetic perspective on biological processes important in parasite survival and host-parasite interactions. In Leishmania, most gene transcription is polycistronic. Transcript abundance measured using microarray techniques will therefore reflect post-transcriptional regulation of gene expression through processes including regulation of mRNA stability. The extent to which transcript abundance reflects ex-Phil. Trans. R. Soc. Lond. B (2002) pression at the protein level has yet to be determined. The first step was to determine whether significant differences in transcript abundance could be measured at the RNA level using microarray techniques.
In the sandfly vector, Leishmania undergoes developmental changes that lead to the generation of infective metacyclic forms transmitted to the vertebrate host. This can be mimicked in culture as promastigote forms of the parasite pass through logarithmic to stationary phases of the growth cycle. To study the developmental changes in transcript abundance, total RNA was prepared from promastigotes at days 3, 5, 7, 10 and 13 of culture and from LAs for L. major LV39.
As a pilot microarrays were produced by spotting PCRamplified inserts from 2091 randomly selected full-length cDNAs from spliced leader libraries prepared from different developmental stages (days 3, 7 and 10 cultured promastigotes L. major LV39; LAs from L. major Friedlin) Levick et al. 1996) . These clones had already been used for EST one-pass 5Ј sequence analysis (Levick et al. 1996; R. Almeida, A. Norrish and J. M. Blackwell, unpublished data) . A complete list of the EST sequences, and the cDNA libraries from which they were derived, can be obtained at http://www.ebi.ac.uk/parasites/ leish.html. Sequence-cluster analysis shows that the 2091 genes represent 1094 unique transcripts, that is, there was around 50% redundancy in the clones selected for random-sequence analysis. For the clustering, a Blastn analysis of all L. major ESTs against the original set (Levick et al. 1996) in the dbEST database was performed. All hits with probabilities Ͻ1e Ϫ10 were initially ranked in descending order of quality. Sequences were then placed in 1094 'pools' (some contain only one entry) on the basis of these data. Leishmania sequences with potentially interesting Blast similarities to constituents of the non-redundant nucleotide, dbEST or Swissprot protein sequence databases comprised 30% of the total EST dataset. These hits represent the 'top' non-self hit obtained for each sequence (the data have been parsed: probability cut-off of 1e Ϫ05 ). Out of these only 23% have significant matches to genes of known functions such that they can be assigned a putative function. Seventy percent of the clones have no sequence identity to any other sequences in the public databases. The 1094 unique genes represent approximately 12% of the total estimated number of Leishmania genes.
To screen the microarrays, a single round of reverse transcription was used to tag RNA transcripts for a particular developmental stage with Cy3. To compare changes in transcript abundance across different developmental stages tested on different microarray 'chips' we had to decide on a control RNA that could be labelled with Cy5 and competitively hybridized with Cy3-labelled 'test' cDNA on every chip. In the initial experiment looking for genes upregulated in expression in amastigotes (figure 1), control RNA was used from a single time-point: day 5 cultured promastigotes of L. donovani LV9. More recently, a pool of RNA across different developmental stages was used for a single outgroup 'control' species; for example, a pool of RNA from actively growing cultures from days 3, 5 and 7 for L. amazonensis has been used to compare changes in transcript abundance for different developmental stages across L. donovani and L. major. Full details of the results of these experiments will be presented elsewhere (Almeida et al., unpublished data) . All of the data will be deposited in the public domain (http://www.ebi.ac.uk/parasites/leish.html) with links that will allow the data to be re-interrogated online at the European Bioinformatics Institute (http://www.ep.ebi.ac.uk/ EP/EPCLUST/). To compare changes in transcript abundance across developmental stages the data were analysed using both hierarchical and partition-based clustering algorithms (Brazma & Vilo 2000) clustering programs make such comparisons, it is useful initially to look at a scatter plot for Cy3 against Cy5 spot intensities for a single developmental stage within a single experiment. Since we want to identify amastigoteexpressed genes for potential vaccine development, the scatter plot for RNA harvested from LA of L. major LV39 (Cy3) against the L. amazonensis RNA pool (Cy5) is of direct relevance (figure 2). Each spot on the scatter plot represents a single cDNA clone. To declare a significant change in transcript abundance between the developmental stages, the ratio of intensity of the Cy3 'test' RNA : Cy5 'control' RNA needs to be greater than +2 or less than Ϫ2, that is, there needs to be more than a twofold enhancement or reduction in transcript abundance comparing 'test' and 'control' RNAs. On the scatter plot this includes the spots above and below the dotted lines. It should be noted, however, that two different spots may have the same absolute intensity for Cy3 (on the y-axis), but one can show more than two-fold enhancement (above the +2-fold dotted line) while the other can show a more than two-fold reduction in intensity compared to their respective Cy5 controls. This will be reflected differently in the patterns of changes in transcript abundance that the cluster analysis will portray (cf. below). Spots that fall within the two dotted lines do not differ significantly in intensity from the control pool, and will cluster around the 'zero' change line on the cluster analysis plots. Again, many of the genes falling within this region will have high absolute intensity on the Cy3 axis. Hence, if the question is simply to ask which genes are expressed in amastigotes, we might choose to set a cut-off on the Cy3 axis above which all genes (= spots) will be considered to be expressed in amastigotes. The stringency of the cut-off above this can be determined according to user requirements; for example, in the initial targeting of amastigoteexpressed genes as vaccine candidates we might choose to set a cut-off a log-fold above the background. However, since we cannot be sure that transcript abundance relates directly to protein abundance, it might be prudent to sample and test genes with both high-and low-transcript abundance.
To obtain an overall profile of the changes in transcript abundance for each gene throughout the developmental cycle we first used partition-based clustering asking the clustering algorithm to cluster our 2091 genes around 10 'seed' clones that it chose as representative of the range of different expression profiles. Figure 1 shows this analysis for the experiment in which the different developmen-Phil. Trans. R. Soc. Lond. B (2002) tal stages for L. major LV39 were each compared against day 5 L. donovani promastigote RNA. The 10 seeds are shown in figure 1j . The program iteratively compares each of the seeds to its next closest matching expression profile, recalculating the cluster means or centres as it goes. The final cluster centres are shown in figure 1l . The 10 resulting clusters are shown in figure 1a -i, k. The profiles show log 2 ratios for fold-increases above and below the control RNA (log 2 of the ratio 1 = 0). The biggest change in expression relative to control for any genes within a cluster are from log 2 = Ϫ1 to log 2 = +4 (figure 1b), that translates to a 32-fold difference in relative abundance for particular genes within the cluster between day 5 promastigotes and amastigotes. The clusters in figure 1b,e,h,k are of particular interest because they contain clusters of genes that appear to be strongly upregulated in abundance in the amastigote stage of the parasite life cycle, and hence might be good vaccine candidates. Looking within these clusters, it can be seen that all redundant clones of the tryparedoxin peroxidase gene fall within cluster 1e (table  1a) , while six out of seven redundant clones of the nucleoside diphosphate kinase B gene fall within cluster 1i (table  1b) . This is reassuring, since it demonstrates remarkable within-experiment reproducibility that extends over all redundant sets of clones within all of our experiments (data not shown). We can then begin to ask questions about what other genes that might be related in function show parallel expression profiles. For example, genes coregulated with nucleoside diphosphate kinase B include histone 4 and the mitotic centromere associated kinensin 2 (table 1b) . This is of interest given that highly conserved homologues of nucleoside diphosphate kinase B occur across prokaryote and eukaryote organisms. It is a dualaction enzyme that maintains the intracellular level of 5Јnucleoside triphosphates (Gilles et al. 1991) and also acts to regulate transcription (Postel et al. 1993) . In Drosophila it is known to regulate cellular differentiation and development (de la Rosa et al. 1995) . It also functions to regulate transcription by the phosphorylation of transcription fac-Phil. Trans. R. Soc. Lond. B (2002) tors in a DNA-dependent manner (Lees-Miller 1996) .
The enzyme is upregulated in Trypanosoma brucei during the S phase of the cell cycle (Gale et al. 1994) , indicating that it plays some role in the cell cycle in trypanosomatids. A more eclectic set of genes cluster with tryparedoxin peroxidase (table 1a) , frustratingly including 66 genes of unknown function that could relate to the antioxidant pathway in which this gene plays a central role (Levick et al. 1998; Alphey et al. 2000) . A more in-depth analysis of this cluster of unknown genes, perhaps lowering the stringent cut-off originally set to declare significant sequence identity, might reveal genes of related function and importance. Experiments could also be performed to determine which of these genes responds to changes in experimentally induced oxidative stress, thus helping to delimit which genes might contribute to antioxidant pathways.
FROM GENES TO VACCINES
The most direct route to taking our putative amastigoteexpressed genes into vaccine testing was to employ a DNA-vaccine strategy. DNA vaccination has already proved successful in vaccinating mice against cutaneous L. major infection (Gurunathan et al. 1997 (Gurunathan et al. , 1998 Handman et al. 2000; Fragaki et al. 2001) . A number of experiments (Norrish et al., unpublished data) have been carried out in our laboratory to refine the DNA-vaccine strategy, in particular to see whether it was possible to reduce both the number and dose of vaccines given. This would facilitate a higher throughput of large numbers of potential vaccine candidates in a murine screen, and allow us to think about pooling strategies to try to identify new vaccine candidates more efficiently. Figure 3 shows the results of one such experiment. Figure 3a shows the normal profile for L. major LV39 infection in susceptible BALB/c compared with genetically resistant CBA/Ca mice. Figure 3b shows that vaccination with 100 g vector DNA alone mimics the BALB/c infection-only profile, whereas vaccination with a single dose of 25 g DNA of a protective antigen lmd29 (plus 75 g vector-only DNA) administered s.c. 6 weeks prior to challenge infection provides significant protection. Figure 3c depicts the infection profiles for eight pools of 4 × 25 g DNA for 16 unknown test vaccines from a 4 × 4 array. Two vaccine pools show some protection relative to the vector-only control; the remaining six pools gave the same infection profile, or showed exacerbation of disease, relative to the vector-only control. Figure 3d shows that the vaccine at the intersect of the two protective pools, designated R61, is protective when administered on its own. This strategy was therefore successful in identifying a new vaccine candidate from the 16 test vaccines in the pools. However, it was also found that protection was lost when 25 g lmd29 was administered in a pool with 25 g each for three members of one of the non-protective pools (data not shown). Hence, there may be antigens within pools that exacerbate disease and mask the potential protective effect of other members of the pool. In current experiments this analysis is being extended by testing the 20 pools obtained in a 10 × 10 array, alongside each of the 100 vaccine candidates tested separately. One advantage of testing all the vaccine candidates separately is that, with the full sequence of all the vaccine candidates to hand, it will be possible to perform a retrospective bioinformatic analysis to see if a predictive algorithm can be devised for what constitutes a successful vaccine candidate for leishmaniasis.
CONCLUSIONS
In the laboratory we have been piloting experiments designed to see whether it is possible to develop global approaches to identify amastigote-expressed genes and carry out large-scale vaccine testing directly utilizing the output of the genome project. The findings thus far have been encouraging, but there is much work ahead to harness the full power of the genome-proteome. In relation to microarray analysis, it is necessary to determine whether expression profiling at the RNA level bears any relation to expression of the protein encoded by the RNA. To examine this we are working with other members of the Leishmania Genome Network to carry out parallel analyses of developmental changes in the transriptome and the proteome using material harvested from the same cultures of parasites. We are also taking some of our protective antigens to see if we can improve vaccine efficiency using a Phil. Trans. R. Soc. Lond. B (2002) DNA-vaccine prime and protein boost strategy (McShane et al. 2001 ) employing attentuated Salmonella typhimurium or Vaccinia virus as the protein-producing vaccine. Clearly the real challenge will be to see how rapidly we can proceed from animal experimentation to phase I and II trials in humans, thus proving the real worth that knowledge of parasite genomes will probably prove to be in relation to human health.
